NTLA Insider Buying — Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”)...

12 insider purchases on record · latest filing 2026-01-05.

Insiders have also filed 284 sale transactions at NTLA.